OrthoPediatrics Reports $61.3M Revenue with 12% Growth, Faces $11.8M Net Loss in Q3 2025

OrthoPediatrics Corp. reported a net revenue of $61.3 million for the third quarter of 2025, marking a 12% increase from $54.6 million in the same period last year. For the nine months ending September 30, 2025, the company achieved a revenue of $174.7 million, a 15% rise from $152.1 million in the prior year. The growth was primarily driven by strong sales in the Trauma and Deformity segment, which saw a 17% increase in quarterly sales, and a 23% increase in Scoliosis product sales for the nine-month period. However, the company also reported a net loss of $11.8 million for the quarter, compared to a loss of $7.9 million in Q3 2024, and a nine-month loss of $29.5 million, up from $21.8 million in the previous year.

The company’s operating expenses increased significantly, with total operating expenses for the third quarter rising to $54.7 million, up from $45.6 million in Q3 2024. This increase was attributed to higher sales and marketing expenses, which grew by 11%, and general and administrative expenses, which rose by 11% as well. Notably, OrthoPediatrics recorded an impairment charge of $2.3 million related to intangible assets, reflecting a strategic decision to exit its regulatory consulting business. The restructuring efforts initiated in 2024 also contributed to increased expenses, with a restructuring charge of $2.3 million recorded in the latest quarter.

In terms of operational developments, OrthoPediatrics has expanded its geographic footprint, now marketing its products in over 75 countries. The company operates approximately 40 orthotic and prosthetic clinics in the U.S. and has established subsidiaries in the Netherlands and Germany to enhance its European operations. The company’s inventory strategy remains focused on consignment sales, which accounted for about 70% of total net sales in the nine months ended September 30, 2025. This model allows the company to maintain control over inventory until it is used in surgical procedures.

The company’s financial position as of September 30, 2025, showed total assets of $493.5 million, up from $473.2 million at the end of 2024. However, cash and cash equivalents decreased to $16.8 million from $43.8 million, reflecting ongoing investments in inventory and operational expansion. OrthoPediatrics has also engaged in significant financing activities, including a $100 million term loan and convertible note agreement with Braidwell LP, which is expected to support its growth initiatives and operational needs.

Looking ahead, OrthoPediatrics anticipates continued investment in product development and market expansion, despite the ongoing operating losses. The company remains focused on enhancing its product offerings and expanding its clinic network, which it believes will strengthen its market position in the pediatric orthopedic sector. Management has indicated that while challenges remain, particularly in achieving profitability, the strategic initiatives in place are expected to drive future growth and operational efficiency.